CompletedNot Applicable

The Effect of Myofascial Chain Release Techniques on Shoulder Joint Range of Motion in Breast Cancer Survivors

Turkey (Türkiye)36 participantsStarted 2022-08-15

Plain-language summary

In breast cancer patients, limitation of shoulder joint movement occurs following mastectomy surgery. Studies have reported that damage to the fascia on the pectoralis major muscle during mastectomy surgery contributes to the development of the limitation. The aim of this study is to investigate the effect of release techniques applied to the fascia on the pectoralis major muscle and the fascial chain on the incerasing of shoulder joint range of motion.

Who can participate

Age range

30 Years – 60 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Women between the ages of 30-60 * Having breast surgery within 2 years * Not have received conservative treatment for shoulder rehabilitation in the last 6 months * Having limitation of movement of the shoulder joint due to breast surgery Exclusion Criteria: * Not having agreed to participate in the study * Having undergone radical mastectomy surgery * Having connective tissue disease * Presence of brachial plexus paresis/plegia * Presence of radiogenic fibrosis * Presence of additional orthopedic (scoliosis, etc.), neurological (multiple sclerosis, stroke, etc.) and rheumatological diseases (ankylosing spondylitis, rheumatoid arthritis, etc.) that will affect upper extremity functions * Presence of active metastases * Having undergone reconstruction surgery * Continuation of radiotherapy (must have ended at least 3 months ago) or chemotherapy applications * Having had a bilateral mastectomy * To develop lymphedema in the arm-trunk * Use of muscle relaxants * Patients with severe chemotherapy side effects (hyperesthesia, nausea, skin changes, weakness, etc.)

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

measurement of tissue stiffness (N/m)

Timeframe: changes from baseline stiffness values will be measured at 6 week and 10 week

measurement of passive muscle tone (Hz)

Timeframe: changes from baseline tone values will be measured at 6 week and 10 week

measurement of creep of tissue

Timeframe: changes from baseline creep values will be measured at 6 week and 10 week

measurement of the range of shoulder joint motion

Timeframe: changes from baseline range of the shoulder joint motion values will be measured at 6 week and 10 week

assessment of activity of daily living

Timeframe: changes from baseline Quick-DASH Questionnaire scores will be assessment at 6 week and 10 week

assessment of depression and anxiety

Timeframe: changes from baseline HAD scale scores will be assessment at 6 week and 10 week

Trial details

NCT IDNCT05386628

SponsorIstanbul Medeniyet University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2025-01-15

View on ClinicalTrials.gov More Breast Cancer Survivors trials